Marc Semigran - 30 Dec 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Development Officer
Signature
/s/ John R. Moore, Attorney-in-Fact for Semigran Marc
Issuer symbol
EWTX
Transactions as of
30 Dec 2022
Net transactions value
$0
Form type
4
Filing time
03 Jan 2023, 15:44:32 UTC
Previous filing
22 Dec 2022
Next filing
18 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 30 Dec 2022 Common Stock 300,000 $8.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option become vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.